ASO Author Reflections: Sarcoma Organoids: Neutralizing the Word "Rare" in Rare Cancers
Ann Surg Oncol
.
2022 Nov;29(12):7368-7369.
doi: 10.1245/s10434-022-12089-9.
Epub 2022 Jul 1.
Authors
Steven D Forsythe
1
2
3
,
Hemamylammal Sivakumar
1
4
,
Richard A Erali
1
3
5
6
,
Aleksander Skardal
1
2
4
7
,
Konstantinos I Votanopoulos
8
9
10
11
12
Affiliations
1
Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
2
Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
3
Wake Forest Organoid Research Center (WFORCE), Winston-Salem, USA.
4
Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA.
5
Department of Surgery, Division of Surgical Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USA.
6
Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, USA.
7
The Ohio State University and Arthur G. James Comprehensive Cancer Center, Columbus, OH, USA.
8
Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA. kvotanop@wakehealth.edu.
9
Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA. kvotanop@wakehealth.edu.
10
Wake Forest Organoid Research Center (WFORCE), Winston-Salem, USA. kvotanop@wakehealth.edu.
11
Department of Surgery, Division of Surgical Oncology, Wake Forest Baptist Health, Winston-Salem, NC, USA. kvotanop@wakehealth.edu.
12
Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, USA. kvotanop@wakehealth.edu.
PMID:
35778628
PMCID:
PMC10071488
DOI:
10.1245/s10434-022-12089-9
No abstract available
Publication types
Comment
MeSH terms
Humans
Organoids
Rare Diseases
Sarcoma*
Soft Tissue Neoplasms*
Grants and funding
T32 CA247819/CA/NCI NIH HHS/United States